Compare TH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | OGN |
|---|---|---|
| Founded | 1978 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2017 | 2020 |
| Metric | TH | OGN |
|---|---|---|
| Price | $13.72 | $6.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $13.00 | $11.75 |
| AVG Volume (30 Days) | 968.5K | ★ 3.2M |
| Earning Date | 05-18-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $320,635,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $12.19 | $0.42 |
| Revenue Next Year | $35.63 | $1.67 |
| P/E Ratio | ★ N/A | $8.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.97 | $5.69 |
| 52 Week High | $14.13 | $13.25 |
| Indicator | TH | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 83.11 | 42.43 |
| Support Level | $7.95 | $5.69 |
| Resistance Level | N/A | $7.87 |
| Average True Range (ATR) | 0.58 | 0.28 |
| MACD | 0.46 | 0.07 |
| Stochastic Oscillator | 94.35 | 62.68 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.